Who is speaking
Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable sharing of knowledge and facilitate idea exchange.
If you have a cutting edge case study or relevant presentation and would like to join the speaker panel at one of our events, please contact Charlotte Tighe at c.tighe@oxfordglobal.co.uk
Confirmed speakers for 2012
- Tudor Arvinte,
CEO, Therapeomic , Professor, University of Geneva - Michel Awwad,
Senior Director, Pfizer - Kevin Brady,
Senior Scientist, Bicycle Therapeutics - Mike Buckley,
VP Process Sciences, Takeda - Naomi Chayen,
Professor, Biomolecular Medicine, Imperial College - Ralph Colby
Professor, Materials Science and Engineering. Penn State University - John Corbin
Associate Director Molecular Interactions and Biophysics, Preclinical Research, Xoma - Ben Davis,
Research Fellow, Vernalis - Rakesh Dixit,
VP, R&D Global Head, MedImmune - Torben Frandsen,
VP, Preclinical R&D Support, Symphogen - Fredrik Frejd,
VP Research, Affibody - Patrick Garidel,
Head of Biopharmaceutical Basic Development, Boehringer Ingelheim - Tariq Ghayur,
Research Fellow, Abbott - Dragan Grabulovski,
CSO, Covagen - Claes Gustafsson,
COO, DNA2.0 - Bruce Hamilton,
Principal Scientist, GSK - Robert Hayes,
VP, Johnson & Johnson - Bernhard Helk,
Director Technology Evaluation, Novartis - Guy Hermans
Principal Scientist, Ablynx - Rene Hoet,
VP Global Biologics, Bayer Schering Pharma - Gavin Jell
Teaching Fellow, UCL - Margit Jeschke,
Head Analytical R&D Biologics, Novartis - Syd Johnson,
VP, Antibody Engineering, Macrogenics - Sergej Kiprijanov
VP Discovery, Research & Preclinical Development, Affitech - Neeraj Kohli,
Group Leader, Principal Scientist, Merrimack - John Lambert,
CSO, ImmunoGen - Alastair Lawson,
VP Structural Biology and Antibody Technology, UCB - Vivian Lindo,
Associate Director, Product Characterisation, MedImmune - Ton Logtenberg
CEO, Merus - Svetlana Lucas,
Director, XOMA - Alex Lugovskoy,
Director of Therapeutic Design, Merrimack Pharmaceuticals - Julian Ma,
Hotung Chair, Molecular Immunology, Joint Head, Infection and Immunity Research Centre, St. George’s, University of London - Glen MacDonald,
Chief Scientific Officer & Vice President, Viventia - David Meininger,
Senior Director Biologics Discovery, Merck - Aline Miller
Senior Lecturer, Manchester University - Frank Mueller,
Senior Manager Biopharmaceutical Projects, Minapharm - Serge Muyldermans,
Group Leader, VIB - Juergen Nett,
Senior Research Fellow, Merck - Jo Nettleship,
Senior Scientist, STRUBI, Oxford University - Sigurd Okkels,
VP, Head of Technical Development, Nycomed - Natasa Przulj
Lecturer, Imperial College - Abbas Razvi
Principal Scientist, Analytical R&D Biologics, Novartis - Joel Richard,
VP Drug Product Development, Pharmaceutical Development, Ipsen - Florence Salmon
Head Non-Clinical Development, Senior Scientist Product Safety, AMT - Professor Inger Sandlie
Deputy Director, Centre for Immune Regulation at University of Oslo - Thomas Schirrmann
Scientist, Technical University of Braunschweig - Jos Seegers,
CEO/CSO, Falco Biotherapeutics - Anthony Shillings,
Principle Scientist, GSK - Arne Skerra,
Professor, TU Munich, CEO & Founder, Pieris - Regis Sodoyer,
Scientist, Sanofi Pasteur - Olivier Soula,
VP, R&D Director, Adocia - John Thompson,
Managing Director, Aldevron Freiburg - Susan Tzotzos,
Research Scientist, Apeptico - Patrick van Berkel,
VP CMC R&D, Genmab - Marijn van der Neut Kolfschoten
Ph.D., Senior Scientist, Crucell - Chris van der Walle
Principal Scientist, MedImmune - Robert Van Monfort,
Team Leader Hit Discovery and Structural Design, Institute of Cancer Research - Bernd Voedisch,
Lab Head, Research, Protein Production, Novartis - Bjorn Voldborg,
Head of Protein Production Unit, NNF-Center for Protein Research, University of Copenhagen - Jim Warwicker
Senior Lecturer, Manchester University - Trevor Wilkinson,
Associate Director, Protein Sciences, MedImmune - Weiming Xu,
Senior Research Associate, University of Sheffield
